 | Up a level |
Michels, S., Gardizi, M., Schultheis, A., Scheffler, M., Karachaliou, N., Teixido, C., Heukamp, L., Merkelbach-Bruse, S., Thurat, M., Nogova, L., Bos, M., Mattonet, C., Grohe, C., Sebastian, M., Thomas, M., Reck, M., Stahel, R., Pirker, R., Zoechbauer-Mueller, S., Groen, H., Dingemanns, A. -M, Smit, E., Thomas, R., Buettner, R., Massuti, B., Rosell, R. and Wolf, J. (2014). EUCROSS: A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262
Michels, S., Thurat, M., Schmalz, P., Pereira, E., Scheffler, M., Fischer, R., Sebastian, M., Abreu, D. R., Carcereny, E., Corral, J. J., Felip, E., Grohe, C., Insa, A., Thomas, M., Reck, M., Rothschild, S., Brandes, V, Nogova, L., Merkelbach-Bruse, S., Massuti, B., Buettner, R., Rosell, R. and Wolf, J. (2016). EUCROSS: A European phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations - Preliminary results. Oncol. Res. Treat., 39. S. 209 - 211. BASEL: KARGER. ISSN 2296-5262